2005
DOI: 10.1016/j.bmc.2005.02.026
|View full text |Cite
|
Sign up to set email alerts
|

Structure–activity relationships and molecular modelling of 5-arylidene-2,4-thiazolidinediones active as aldose reductase inhibitors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

4
62
1
1

Year Published

2006
2006
2022
2022

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 110 publications
(68 citation statements)
references
References 26 publications
4
62
1
1
Order By: Relevance
“…Calf lenses for the isolation of ALR 2 were obtained locally from freshly slaughtered animals. The enzyme was purified by a chromatographic procedure as previously described [10]. Enzyme activities were assayed on a Cecil Super Aurius CE 3041 spectrophotometer (Cecil Instruments, Cambridge, England) by measuring the decrease in absorption of NADPH at 340 nm which accompanies the oxidation of NADPH catalyzed by ALR 2.…”
Section: General Procedures For the Synthesis Of The Target Compounds mentioning
confidence: 99%
“…Calf lenses for the isolation of ALR 2 were obtained locally from freshly slaughtered animals. The enzyme was purified by a chromatographic procedure as previously described [10]. Enzyme activities were assayed on a Cecil Super Aurius CE 3041 spectrophotometer (Cecil Instruments, Cambridge, England) by measuring the decrease in absorption of NADPH at 340 nm which accompanies the oxidation of NADPH catalyzed by ALR 2.…”
Section: General Procedures For the Synthesis Of The Target Compounds mentioning
confidence: 99%
“…For these reasons, there is still a need to identify and develop clinically effective and well-tolerated ARIs [7,8]. QSAR studies of 2,4-dioxo-5-(naphth-2-ylmethylene)-3-thiazolidinyl acetic acids and 2-thioxo analogues [9] ( Fig.…”
Section: Introductionmentioning
confidence: 99%
“…Крім того, серед 5-арилідензаміщених родані-нів відомі інгібітори HCV NS5b (Hepatitis C Virus Nonstructural) полімерази IV (IC 50 = 1,5 мкМ) [9] та HCV NS3-протеази V (IC 50 = 6,4 мкМ) [10] як перспективні противірусні агенти, високоактивні сполуки з протипухлинною [11,12], протизапаль-ною [13] та антималярійною [14] дією, а також інгібітори альдозоредуктази [15] та агоністи PPARγ рецепторів [16] як потенційні терапевтич-ні агенти у лікуванні цукрового діабету та його ускладнень.…”
unclassified